Navigation Links
ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Date:3/3/2009

In ClearTrial v2.7, the newest version of the award-winning clinical trial software, ClearTrial introduces Portfolio Planning capability which enables clinical development organizations to roll up protocol-level study plans into portfolio-level forecasts in minutes. The software provides instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension - a capability unique to the industry.

Chicago (PRWEB) March 3, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that it has released version 2.7 of its market-leading ClearTrial clinical trial software, which helps biopharmaceutical companies and clinical research organizations (CROs) accelerate and improve the planning and execution of their clinical trials. Today, 6 of the top 10 biotech companies and many of the largest companies in the industry rely on ClearTrial software to bring quality treatments to market faster, with less cost and effort.

With ClearTrial Portfolio Planning, available in the Enterprise Edition of ClearTrial v2.7, clinical development organizations can now roll up protocol-level study plans into portfolio-level forecasts in minutes, providing instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension - a capability unique to the industry. And when protocol-level assumptions change, the software automatically updates the portfolio forecast in seconds.

With ClearTrial Portfolio Planning, clinical trial professionals can:

  • Aggregate multiple studies into a program/portfolio view or long-range plan
  • Generate comprehensive monthly budget, resource, and timeline reports
  • Add or remove studies from a portfolio
  • Modify study start dates
  • Adjust study probabilities

"ClearTrial Portfolio Planning gives life sciences companies a lightning-fast and more informed portfolio and program decision-making capability that presents a major competitive advantage, especially in today's economic climate," noted Mike Soenen, Managing Partner of ClearTrial. "The pressure to move faster with fewer resources has never been greater and with Portfolio Planning, ClearTrial is again first in class to answer that challenge."

Key Benefits of ClearTrial Portfolio Planning
For clinical operations, outsourcing, finance, and project/resource management professionals at life sciences organizations, ClearTrial Portfolio Planning offers:

Integrated Roll-up for Increased Accuracy and Speed - The software eliminates errors in the time-consuming re-keying involved with manually rolling up multiple study plans into program- or company-wide forecasts. ClearTrial Portfolio Planning also ensures that planners are using the most current information by automatically updating the portfolio forecast with any changes made to the protocol-level assumptions.

Effortless Cost and Resource Demand Forecasting Across the Organization - Monthly cost and resource demand forecasts enable companies to easily identify areas of heavy FTE utilization, and more proactively hire or contract for additional resources - or modify study start dates to smooth out resource utilization. Planners can instantly see the budget and resource impact of dropping or delaying a study or group of studies, immediately assess the result on hours and fees, by month, of outsourcing all monitoring, and more.

Flexibility to Support Business Objectives and Processes - ClearTrial Portfolio Planning enables the creation of portfolios along any clinical development dimension to:

  • Compare portfolios for multiple long-range planning scenarios
  • Assign probability weighting to in-licensing and out-licensing deals
  • Accurately model later-stage studies that are dependent on early study success for more accurate stage-gate decision-making
  • Assess program-level outsourcing strategies

"With version 2.7, ClearTrial continues to set the standard for clinical software that helps life sciences companies bring new, quality treatments to market more rapidly," Soenen stated. "We're pleased to introduce this much-needed capability to the benefit of the industry."

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

###

Read the full story at http://www.prweb.com/releases/2009/03/prweb2201104.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
2. Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimers Disease
3. Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol
4. EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention
5. Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement
6. CUREXO Technology Corporation Launches Its ROBODOC(R) Surgical System at Upcoming Orthopaedic Conference in Las Vegas
7. BioSpace.com Launches a New Season of Industry Career Fairs
8. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
9. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
10. Cephalons New Product Launches Pace Record 2008 Sales
11. BioComp Pharma Launches First Generic Drug for Tindamax(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... /PRNewswire -- WuXi AppTec, a leading global pharmaceutical, ... platform, today announced that it has acquired HD ... discovery contract research organization (CRO). After completion of ... of WuXi, and will continue to focus on ... The acquisition will further strengthen WuXi,s R&D capability ...
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... with services spanning the full spectrum of drug and device development, and ... to pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal ... using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining ... a compact business-card sized form factor suitable for prototyping, testing, and production-ready integration. ...
Breaking Biology Technology:
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
Breaking Biology News(10 mins):